DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Japan Procedure Numbers for Gynecological Devices 2017 - MedPro" report to their offering.
Despite Japan's preference to invest in high-end medical devices, the gynecology device market is constrained by the lack of training, diversity in alternative procedures and investment in specialty equipment. The predominant shift towards capital equipment that can be used off label across procedure types is both limiting capital equipment sales and access to preferred treatment options in 2016.
The assisted reproduction technology device market comprised 66.8% of the overall market for gynecological devices in 2016. The investment in cutting edge technology fueled by exponential patient demand has led to increasing patient growth across all five market segments. The treatment cycles covered in the ART market include IVF, ICSI and FER cycles. Additionally, the ART market is being heavily impacted by numerous mergers and acquisitions, creating monopolies on prices and market shares.
Japan has the highest rate for uterine fibroid embolization procedures worldwide. The preference for UFE is the most pronounced in Japan; however, this trend is true throughout Asia and Oceania. The influence of embolization technology and newly approved devices is carrying over into the field of gynecology. The markets for endometrial resection and the emergence of endometrial ablation are projected to cannibalize UFE procedures over the forecast period.
Key Topics Covered:
1. Research Methodology
2. Disease Overview
3. Procedure Numbers
For more information about this report visit http://www.researchandmarkets.com/research/7cblhf/japan_procedure